RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Tianjin Pharmaceutical Da Ren Tang Group Corp Stock

Tianjin Pharmaceutical Da Ren Tang Group Corp Equity 2024

Tianjin Pharmaceutical Da Ren Tang Group Corp Equity

6.6 B CNY

Ticker

600329.SS

ISIN

CNE000001808

In 2024, Tianjin Pharmaceutical Da Ren Tang Group Corp's equity was 6.6 B CNY, a 1.21% increase from the 6.52 B CNY equity in the previous year.

Tianjin Pharmaceutical Da Ren Tang Group Corp Aktienanalyse

What does Tianjin Pharmaceutical Da Ren Tang Group Corp do?

Tianjin Zhongxin Pharmaceutical Group Corp Ltd is one of the leading pharmaceutical companies in China. It was founded in 1994 and is headquartered in the city of Tianjin in the northern part of the country. Zhongxin is a publicly traded company and employs over 6,000 employees. The business model of Zhongxin is diversified and includes manufacturing, research and development, sales, and marketing of pharmaceuticals and medical devices. The company strives to provide its customers with high-quality products and services and operates in various specialized areas. One of Zhongxin's main divisions is the manufacturing of pharmaceutical products. The company specializes in the production of cardiology, gastroenterology, oncology, and traditional Chinese medicines. Zhongxin operates multiple production facilities in China and has a productive R&D department focused on drug development. Another important part of Zhongxin's business is the distribution of its products. The company operates several distribution centers in China and is also increasing its presence in international markets. Distribution is done either directly to end customers or through intermediaries. In addition to the sale of medications, Zhongxin is also involved in medical wholesale activities, including retail and delivery of medical equipment and instruments. The company is capable of providing all types of medical devices and instruments from imaging and diagnostics to surgical instruments and implants. Zhongxin also has a specialized chemicals and raw materials division focused on the production of pharmaceutical active ingredients and intermediates. This gives the company additional control over the quality of its products as it is able to produce raw materials itself. The company is always seeking new innovations and heavily investing in research and development. In recent times, Zhongxin has invested in the development of biotech and nucleic acid therapies and intends to develop further innovative treatment methods. Zhongxin has also developed a strong presence in international markets in recent years. It has subsidiaries in several countries including the USA, Australia, Japan, and Europe. The company engages in joint ventures and strategic partnerships to enhance its raw material procurement and expand its reach internationally. Overall, Tianjin Zhongxin Pharmaceutical Group Corp Ltd is a significant player in the pharmaceutical industry in China and on the international stage. The company has established a reputation as a reliable producer of high-quality medical products and services and continues to strive for success through innovation and expansion. Tianjin Pharmaceutical Da Ren Tang Group Corp ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Tianjin Pharmaceutical Da Ren Tang Group Corp's Equity

Tianjin Pharmaceutical Da Ren Tang Group Corp's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Tianjin Pharmaceutical Da Ren Tang Group Corp's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Tianjin Pharmaceutical Da Ren Tang Group Corp's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Tianjin Pharmaceutical Da Ren Tang Group Corp's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Tianjin Pharmaceutical Da Ren Tang Group Corp’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Tianjin Pharmaceutical Da Ren Tang Group Corp stock

What is the equity of Tianjin Pharmaceutical Da Ren Tang Group Corp this year?

Tianjin Pharmaceutical Da Ren Tang Group Corp has equity of 6.6 B CNY this year.

What was the equity of Tianjin Pharmaceutical Da Ren Tang Group Corp compared to the previous year?

The equity of Tianjin Pharmaceutical Da Ren Tang Group Corp has increased/decreased by 1.21% increased compared to the previous year.

What impact does a high equity have on investors of Tianjin Pharmaceutical Da Ren Tang Group Corp?

A high equity is advantageous for investors of Tianjin Pharmaceutical Da Ren Tang Group Corp as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Tianjin Pharmaceutical Da Ren Tang Group Corp?

A low equity can be a risk for investors of Tianjin Pharmaceutical Da Ren Tang Group Corp, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Tianjin Pharmaceutical Da Ren Tang Group Corp affect the company?

An increase in equity of Tianjin Pharmaceutical Da Ren Tang Group Corp can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Tianjin Pharmaceutical Da Ren Tang Group Corp affect the company?

A reduction in equity of Tianjin Pharmaceutical Da Ren Tang Group Corp can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Tianjin Pharmaceutical Da Ren Tang Group Corp?

Some factors that can affect the equity of Tianjin Pharmaceutical Da Ren Tang Group Corp include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Tianjin Pharmaceutical Da Ren Tang Group Corp so important for investors?

The equity of Tianjin Pharmaceutical Da Ren Tang Group Corp is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Tianjin Pharmaceutical Da Ren Tang Group Corp take to change the equity?

To change equity, Tianjin Pharmaceutical Da Ren Tang Group Corp can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Tianjin Pharmaceutical Da Ren Tang Group Corp pay?

Over the past 12 months, Tianjin Pharmaceutical Da Ren Tang Group Corp paid a dividend of 1.12 CNY . This corresponds to a dividend yield of about 3.47 %. For the coming 12 months, Tianjin Pharmaceutical Da Ren Tang Group Corp is expected to pay a dividend of 1.21 CNY.

What is the dividend yield of Tianjin Pharmaceutical Da Ren Tang Group Corp?

The current dividend yield of Tianjin Pharmaceutical Da Ren Tang Group Corp is 3.47 %.

When does Tianjin Pharmaceutical Da Ren Tang Group Corp pay dividends?

Tianjin Pharmaceutical Da Ren Tang Group Corp pays a quarterly dividend. This is distributed in the months of July, July, July, August.

How secure is the dividend of Tianjin Pharmaceutical Da Ren Tang Group Corp?

Tianjin Pharmaceutical Da Ren Tang Group Corp paid dividends every year for the past 16 years.

What is the dividend of Tianjin Pharmaceutical Da Ren Tang Group Corp?

For the upcoming 12 months, dividends amounting to 1.21 CNY are expected. This corresponds to a dividend yield of 3.75 %.

In which sector is Tianjin Pharmaceutical Da Ren Tang Group Corp located?

Tianjin Pharmaceutical Da Ren Tang Group Corp is assigned to the 'Health' sector.

Wann musste ich die Aktien von Tianjin Pharmaceutical Da Ren Tang Group Corp kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Tianjin Pharmaceutical Da Ren Tang Group Corp from 7/12/2024 amounting to 1.28 CNY, you needed to have the stock in your portfolio before the ex-date on 7/12/2024.

When did Tianjin Pharmaceutical Da Ren Tang Group Corp pay the last dividend?

The last dividend was paid out on 7/12/2024.

What was the dividend of Tianjin Pharmaceutical Da Ren Tang Group Corp in the year 2023?

In the year 2023, Tianjin Pharmaceutical Da Ren Tang Group Corp distributed 0.5 CNY as dividends.

In which currency does Tianjin Pharmaceutical Da Ren Tang Group Corp pay out the dividend?

The dividends of Tianjin Pharmaceutical Da Ren Tang Group Corp are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Tianjin Pharmaceutical Da Ren Tang Group Corp

Our stock analysis for Tianjin Pharmaceutical Da Ren Tang Group Corp Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Tianjin Pharmaceutical Da Ren Tang Group Corp Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.